Suppr超能文献

甲状腺乳头状癌中[具体内容]的临床效果及其与V600E突变的相关性:一项病例对照研究

Clinical effect of and its relevance to V600E mutation in papillary thyroid carcinoma: a case-control study.

作者信息

Li Quan, Jin Wen-Xu, Jin Yi-Xiang, Zheng Zhou-Ci, Zhou Xiao-Fen, Wang Qing-Xuan, Ye Dan-Rong, Sun Yi-Han, Zhang Xiao-Hua, Wang Ou-Chen, Chen En-Dong, Cai Ye-Feng

机构信息

Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

出版信息

Cancer Manag Res. 2018 May 29;10:1351-1358. doi: 10.2147/CMAR.S161501. eCollection 2018.

Abstract

AIM

To investigate the clinical effects of on papillary thyroid cancer (PTC) and explore the relationship between expression and mutation.

METHODS

The data of 69 patients subjected to fine-needle aspiration biopsy in our hospital and 486 patient data downloaded from The Cancer Genome Atlas (TCGA) database were used. Univariate and multivariate analyses were performed.

RESULTS

The results on the 486 patients recorded in the TCGA indicated that high expression was independently related to mutation, lymph node metastasis (LNM), and unifocal type. In the 69 fine-needle aspiration biopsy patients with PTC, high expression was significantly related to LNM and extrathyroid extension (ETE). The result of Pearson's correlation coefficient showed that mutation and expression were moderately correlated. Moreover, in the subgroup with low expression, the patients with mutation had higher ETE frequency and LNM than those without mutation. In the subgroup with mutation, patients with high expression exhibited higher ETE frequency than those with low expression, and high expression occurred in older patients. In the subgroup with wild-type mutation, patients with high expression had a higher incidence of ETE and LNM than those with low expression.

CONCLUSION

We demonstrated that the is an important oncogene in PTC and may have great significance on therapeutic cancer vaccine development.

摘要

目的

研究[具体内容]对甲状腺乳头状癌(PTC)的临床影响,并探讨[具体内容]表达与[具体内容]突变之间的关系。

方法

使用我院69例行细针穿刺活检患者的数据以及从癌症基因组图谱(TCGA)数据库下载的486例患者数据。进行单因素和多因素分析。

结果

TCGA记录的486例患者的结果表明,高[具体内容]表达与[具体内容]突变、淋巴结转移(LNM)和单灶型独立相关。在69例PTC细针穿刺活检患者中,高[具体内容]表达与LNM和甲状腺外侵犯(ETE)显著相关。Pearson相关系数结果显示,[具体内容]突变与[具体内容]表达呈中度相关。此外,在低[具体内容]表达亚组中,有[具体内容]突变的患者ETE频率和LNM高于无[具体内容]突变的患者。在有[具体内容]突变的亚组中,高[具体内容]表达的患者ETE频率高于低[具体内容]表达的患者,且高[具体内容]表达发生在老年患者中。在有[具体内容]野生型突变的亚组中,高[具体内容]表达的患者ETE和LNM发生率高于低表达患者。

结论

我们证明[具体内容]是PTC中的一个重要癌基因,可能对治疗性癌症疫苗的开发具有重要意义。

相似文献

1
Clinical effect of and its relevance to V600E mutation in papillary thyroid carcinoma: a case-control study.
Cancer Manag Res. 2018 May 29;10:1351-1358. doi: 10.2147/CMAR.S161501. eCollection 2018.
4
Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma.
Oncol Lett. 2021 Mar;21(3):188. doi: 10.3892/ol.2021.12449. Epub 2021 Jan 6.
5
Predictive Value of BRAF Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.
Curr Med Sci. 2018 Oct;38(5):785-797. doi: 10.1007/s11596-018-1945-7. Epub 2018 Oct 20.
6
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
J Clin Endocrinol Metab. 2021 Oct 21;106(11):3228-3238. doi: 10.1210/clinem/dgab286.
8
BRAF V600E and lymph node metastases in papillary thyroid cancer.
Endocr Connect. 2020 Oct;9(10):999-1008. doi: 10.1530/EC-20-0420.
9
Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation.
Front Endocrinol (Lausanne). 2022 Jun 16;13:884428. doi: 10.3389/fendo.2022.884428. eCollection 2022.
10
A novel tumor suppressor gene is correlated with progression in papillary thyroid carcinoma.
Onco Targets Ther. 2018 Jan 11;11:307-311. doi: 10.2147/OTT.S154158. eCollection 2018.

引用本文的文献

1
The multifaceted role of MUC1 in tumor therapy resistance.
Clin Exp Med. 2023 Sep;23(5):1441-1474. doi: 10.1007/s10238-022-00978-y. Epub 2022 Dec 23.
2
Amphicrine Medullary Thyroid Carcinoma - a Case-Based Review Expanding on Its MUC Expression Profile.
Endocr Pathol. 2022 Sep;33(3):378-387. doi: 10.1007/s12022-022-09725-1. Epub 2022 Jun 23.

本文引用的文献

1
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress.
Biochem Biophys Res Commun. 2013 Oct 11;440(1):179-83. doi: 10.1016/j.bbrc.2013.09.055. Epub 2013 Sep 18.
5
MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.
J Biol Chem. 2013 Oct 25;288(43):30892-903. doi: 10.1074/jbc.M113.477158. Epub 2013 Sep 16.
7
Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.
J Cancer Epidemiol. 2013;2013:965212. doi: 10.1155/2013/965212. Epub 2013 May 7.
8
Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.
Ann Surg Oncol. 2012 Jun;19(6):1874-80. doi: 10.1245/s10434-011-2129-x. Epub 2011 Nov 8.
9
Molecular genetics and diagnosis of thyroid cancer.
Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80. doi: 10.1038/nrendo.2011.142.
10
Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules.
J Clin Endocrinol Metab. 2011 Jul;96(7):2016-26. doi: 10.1210/jc.2010-2567. Epub 2011 May 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验